Follow-up of aspirin-resistant patients with end-stage kidney disease

International Urology and Nephrology

Volumn 45, Issue 4, 2013, Pages 1097-1102

  Kilickesmez, Kadriye Orta ^a   Kocas, Cuneyt ^a   Abaci, Okay ^a   Okcun, Baris ^a   Gorcin, Bilal ^b   Gurmen, Tevfik ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Hizmet Hospital   (Turkey)

Author keywords

Aspirin resistance; End stage kidney disease; Platelet function

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEATH; DISEASE COURSE; DRUG EFFECT; DRUG RESISTANCE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA, UNSTABLE; AREA UNDER CURVE; ASPIRIN; CAUSE OF DEATH; COHORT STUDIES; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK ASSESSMENT; STROKE; SURVIVAL RATE;

EID: 84881480120     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-012-0217-x     Document Type: Article

References (24)

1. Antithrombotic Trialists' Collaboration (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373:1849-1860
2. Gasparyan AY, Watson T, Lip GY (2008) The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 51:1829-1843
3. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39:S1-266
4. Luke RG (1998) Chronic renal failure-a vasculopathic state. N Engl J Med 339:841-843
5. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR (2008) Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336:195-198
6. Tóth O, Calatzis A, Penz S, Losonczy H, Siess W (2006) Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 96:781-788
7. Sibbing D, Braun S, Jawansky S, Vogt W, Mehilli J, Schömig A, Kastrati A, von Beckerath N (2008) Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 99:121-126
8. von Pape KW, Dzijan-Horn M, Bohner J, Spannagl M, Weisser H, Calatzis A (2007) Control of aspirin effect in chronic cardiovascular patients using two whole blood platelet function assays. PFA-100 and Multiplate. Hamostaseologie 27:155-160
9. Jámbor C, Weber CF, Gerhardt K, Dietrich W, Spannagl M, Heindl B, Zwissler B (2009) Whole blood multiple electrode aggregometry is a reliable point-of-care test of aspirin-induced platelet dysfunction. Anesth Analg 109:25-31
10. Chamorro A, Blanc R, Ascaso C, Saiz A, Vila N (1997) Factors associated to aspirin failure for secondary stroke prevention. Med Clin (Barc) 109:569-572
11. Buchanan MR, Brister SJ (1995) Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 11:221-227
12. Cipollone F, Patrignani P, Greco A, Panara MR, Padovano R, Cuccurullo F, Patrono C, Rebuzzi AG, Liuzzo G, Quaranta G, Maseri A (1997) Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation 96:1109-1116
13. Grotemeyer KH, Scharafinski HW, Husstedt IW (1993) Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 71:397-403
14. Fateh-Moghadam S, Plöckinger U, Cabeza N, Htun P, Reuter T, Ersel S, Gawaz M, Dietz R, Bocksch W (2005) Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 42:99-103
15. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41:961-965
16. Roth GJ, Majerus PW (1975) The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 56:624-632
17. Kawasaki T, Ozeki Y, Igawa T, Kambayashi J (2000) Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 31:591-595
18. Cambria-Kiely JA, Gandhi PJ (2002) Aspirin resistance and genetic polymorphisms. J Thromb Thrombolysis 14:51-58
19. Cambria-Kiely JA, Gandhi PJ (2002) Possible mechanisms of aspirin resistance. J Thromb Thrombolysis 13:49-56
20. Bloom A, Greaves M, Preston FE, Brown CB (1986) Evidence against a platelet cyclooxygenase defect in uraemic subjects on chronic haemodialysis. Br J Haematol 62:143-149
21. Cavarape A, Bauer J, Bartoli E, Endlich K, Parekh N (2003) Effects of angiotensin II, arginine vasopressin and tromboxane A2 in renal vascular bed: role of rho-kinase. Nephrol Dial Transplant 18:1764-1769
22. Geara AS, Azzi N, Bassil C, El-Sayegh S (2010) Aspirin resistance in hemodialysis patients. Int Urol Nephrol. doi: 10.1007/s11255-010-9811
23. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Clopidogrel in effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494-502
24. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ, CREDO Investigators (2002) Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288:2411-2420